An observational study in Lipid-Rich Atherosclerosis of Coronary Artery, sponsored by National Cerebral and Cardiovascular Center, Japan. Recruiting at 2 sites in Japan. Open to participants aged 20 Years to 95 Years. Per ClinicalTrials.gov, last updated 2025-08-15.
Sponsored by National Cerebral and Cardiovascular Center, Japan · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 134 studies in Coronary Artery Disease with a site in Japan — 12 open to participants now, 21 under way, 2 of them phase 3. Coronary Artery Disease · Japan.
Among the 134 studies in Coronary Artery Disease with a site in Japan, this one is the 7th largest by planned enrollment of the 34 observational ones that give a count, is one of 12 that started in 2018, is one of 34 observational ones, reaches primary completion later than 15 of the 20 other live ones, and was the 124th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →12 of the 134 studies in Coronary Artery Disease with a site in Japan are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Japan, United States, Australia and 2 more countries
Ages 18–80
Medtronic Vascular · Sites in Japan, United States, Canada and 6 more countries
Ages 18+
CSL Behring · Sites in Japan, United States, Argentina and 32 more countries
Ages 18+
Seung-Jung Park · Sites in Japan, Hong Kong, India and 2 more countries
Ages 20+
Weill Medical College of Cornell University · Sites in Japan, United States, Australia and 23 more countries
Ages 18+ · Women only
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 20 Years to 95 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
134 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 17 · Phase 4 36
First in 1996; this study’s year is marked. 12 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 445 across the 100 interventional studies, 431 across the 34 observational. Of the 91 that completed or were terminated, 36 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 134 have an industry lead sponsor. The 10 most frequent:
National Cerebral and Cardiovascular Center, Japan is the lead sponsor of 19 studies on the registry; 3 are open to participants now.
National Cerebral and Cardiovascular Center, Japan has 2 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Coronary Artery Disease with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03820492Insel Gruppe AG, University Hospital BernComparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT | 2026-12-31 |
| NCT06535854Medtronic VascularPrevail Global Study | 2027-02 |
| NCT05829889Seung-Jung ParkFractional Flow Reserve Versus Angiography for Treatment-Decision and Evaluation of Significant Left MAIN Coronary Artery Disease | 2027-06 |
| NCT07830719Novartis PharmaceuticalsDose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP | 2027-08-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 134 studies in Coronary Artery Disease with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
RESSURE-NIRS registry is designed to investigate clinical and pathophysiological characteristics of NIRS-derived lipid-rich plaque in patients with coronary artery disease. This is an on-going multi-center prospective registry in Japan.
NIRS imaging is an invasive intravascular imaging modality to quantitatively visualize lipid-rich atheroma in vivo. While NIRS-derived lipid-rich plaque has been shown to associate with cardiovascular events, there is limited clinical data about the association of this high-risk plaque with risk factors, medication use, prognosis and response of PCI. RESSURE-NIRS registry is an on-going multi-center prospective registry in Japan, which enroll subjects with coronary artery disease who received NIRS imaging to evaluate coronary atherosclerosis. The primary outcome is maximum 4-mm lipid core burden index at coronary lesions measured by NIRS imaging. Secondary major outcomes include entire lipid core burden index, plaque volume, plaque attenuation and echo-lucent area. The anticipated number of study subjects is 2000 cases.
Study population should be patients with coronary artery disease who requires coronary angiography and/or percutaneous coronary intervention with NIRS imaging
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
patients with coronary artery disease clinical indication for coronary angiography and/or percutaneous coronary intervention visualization of coronary lesions with NIRS
Exclusion Criteria:
poor quality of NIRS images
Near-infrared spectroscopy is an intravascular imaging device to visualize lipid-rich plaque of coronary artery.
MACE
major adverse cardiovascular events (=cardiac-cause death, non-fatal MI and clinically-driven non-restenotic coronary revascularization)
Time frame: at an average of 3 year
Coronary physiological characteristics at lipid-rich plaques
Identify and quantify coronary physiological findings (=fractional flow reserve and delta fractional flow reserve) for cardiovascular risk stratification of persons with lipid-rich plaques.
Time frame: Physiological measures are collected during the procedure: percutaneous coronary intervention
The occurrence of MACE in patients who achieved LDL-C <1.4 mmol/L
The efficacy of LDL-C \<1.4 mmol/L on MACE
Time frame: at an average of 2 year
gender difference in NIRS-derived measures
sex-related difference in maxLCBI
Time frame: NIRS-derived measures are collected during the procedure
Plan to share: Undecided
Started Oct 2018 (actual). Primary completion is estimated for Dec 2028, 122 months after the start.
Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 122 months is above that.
Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Cerebral and Cardiovascular Center, Japan